Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 55Lung Neoplasms 32Breast Neoplasms 29Small Cell Lung Carcinoma 23Neoplasms 21Triple Negative Breast Neoplasms 18Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Melanoma 14Colorectal Neoplasms 14Glioblastoma 10Prostatic Neoplasms 9Ovarian Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Liver Neoplasms 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Mesothelioma, Malignant 7Uterine Cervical Neoplasms 6Sarcoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Kidney Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Squamous Cell 5Pancreatic Neoplasms 4

Interventions

lutetium Lu 177 dotatate 43-Iodobenzylguanidine 4anlotinib 3gallium Ga 68 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Phenoxybenzamine 2Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1pembrolizumab 1olaparib 1lanreotide 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1Vorinostat 1Specimen Handling 1Radiosurgery 1Interleukin-13 1Genetic Testing 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraganglioma × atezolizumab × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡